Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer's disease: Implications for synaptic dysfunction and neuronal damage

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 12, 2013, Pages 1913-1921

  Reddy, P Hemachandra ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Amyloid beta precursor protein; Glycogen synthase kinase 3beta; Mitochondria; Voltage dependent anion channel 1

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; HEXOKINASE; PROTEIN KINASE B; VOLTAGE DEPENDENT ANION CHANNEL 1;

ALZHEIMER DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW;

EID: 84882738357     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.06.012     Document Type: Review

References (131)

1. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
2. Alzheimer Association Alzheimer's Disease: Facts and Figures 2013.
3. Reddy P.H., Tripathi R., Troung Q., Tirumala K., Reddy T.P., Anekonda V., Shirendeb U.P., Calkins M.J., Reddy A.P., Mao P., Manczak M. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim. Biophys. Acta 2012, 1822:639-649.
4. LaFerla F.M., Green K.N., Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 2007, 499-509.
5. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
6. Reddy P.H., Beal M.F. Are mitochondria critical in the pathogenesis of Alzheimer's disease?. Brain Res. Brain Res. Rev. 2005, 49:618-632.
7. Reddy P.H., Manczak M., Mao P., Calkins M.J., Reddy A.P., Shirendeb U. Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline. J. Alzheimers Dis. 2010, 20:S499-S512.
8. Reddy P.H. Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. Antioxid. Redox Signal. 2007, 9:1647-1658.
9. Reddy P.H., Beal M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol. Med. 2008, 14:45-53.
10. Du H., Guo L., YaN S.S. Synaptic mitochondrial pathology in Alzheimer's disease. Antioxid. Redox Signal. Jun 15 2012, 16(12):1467-1475.
11. Swerdlow R.H. Brain aging, Alzheimer's disease, and mitochondria. Biochim. Biophys. Acta 2011, 1812:1630-1639.
12. Zhu X., Perry G., Smith M.A., Wang X. Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J. Alzheimers Dis. 2013, 33(Suppl. 1):S253-S262.
13. DaRocha-Souto B., Coma M., Pérez-Nievas B.G., Scotton T.C., Siao M., Sánchez-Ferrer P., Hashimoto T., Fan Z., Hudry E., Barroeta I., Serenó L., Rodríguez M., Sánchez M.B., Hyman B.T., Gómez-Isla T. Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease. Neurobiol. Dis. 2012, 45:425-437.
14. Sofola O., Kerr F., Rogers I., Killick R., Augustin H., Gandy C., Allen M.J., Hardy J., Lovestone S., Partridge L. Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet. 2012, 6. (doi: pii: e1001087).
15. Hurtado D.E., Molina-Porcel L., Carroll J.C., Macdonald C., Aboagye A.K., Trojanowski J.Q., Lee V.M. Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. J. Neurosci. 2012, 32:7392-7402.
16. Martinez A., Perez D.J. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?. J. Alzheimers Dis. 2008, 15:181-191.
17. Kremer A., Louis J.V., Jaworski T., Van Leuven F. GSK3 and Alzheimer's disease: facts and fiction. Front. Mol. Neurosci. 2011, 4:17.
18. Inestrosa N.V., Arenas E. Emerging roles of Wnts in the adult nervous system. Nat. Rev. Neurosci. 2010, 11:77-86.
19. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
20. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
21. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8850-8855.
22. McGeer P.L., McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev. 1995, 21:195-218.
23. Launer L.J. Nonsteroidal anti-inflammatory drugs and Alzheimer disease: what's next?. JAMA 2003, 289:2865-2867.
24. Gasparini L., Ongini E., Wenk G. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J. Neurochem. 2004, 91:521-536.
25. Gasparini L., Ongini E., Wilcock D., Morgan D. Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Res. Brain Res. Rev. 2005, 48:400-408.
26. Nakashima H., Ishihara T., Yokota O., et al. Effects of alphatocopherol on an animal model of tauopathies. Free Radic. Biol. Med. 2004, 37:176-186.
27. Conte V., Uryu K., Fujimoto S., Yao Y., Rokach J., Longhi L., Trojanowski J.Q., Lee V.M., McIntosh T.K., Praticò D. Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. J. Neurochem. 2004, 90:758-764.
28. Sung S., Yao Y., Uryu K., Yang H., Lee V.M., Trojanowski J.Q., Pratico D. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J. 2004, 18:323-325.
29. Matsubara E., Bryant-Thomas T., Pacheco Quinto J., et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J. Neurochem. 2003, 85:1101-1108.
30. Stackman R.W., Eckenstein F., Frei B., Kulhanek D., Nowlin J., Quinn J.F. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp. Neurol. 2003, 184:510-520.
31. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., Chen P.P., Kayed R., Glabe C.G., Frautschy S.A., Cole G.M. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005, 280:5892-5901.
32. Morris M.C., Beckett L.A., Scherr P.A., Hebert L.E., Bennett D.A., Field T.S., Evans D.A. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1998, 12:121-126.
33. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennett D.A., Aggarwal N., Wilson R.S., Scherr P.A. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002, 287:3230-3237.
34. Morris M.C., Evans D.A., Tangney C.C., Bienias J.L., Wilson R.S., Aggarwal N.T., Scherr P.A. Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. Am. J. Clin. Nutr. 2005, 81:508-514.
35. Grundman M., Petersen R.C., Ferris S.H., Thomas R.G., Aisen P.S., Bennett D.A., Foster N.L., Jack C.R., Galasko D.R., Doody R., Kaye J., Sano M., Mohs R., Gauthier S., Kim H.T., Jin S., Schultz A.N., Schafer K., Mulnard R., van Dyck C.H., Mintzer J., Zamrini E.Y., Cahn-Weiner D., Thal L.J. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch. Neurol. 2004, 61:59-66.
36. Zandi P.P., Anthony J.C., Khachaturian S., Stone S.V., Gustafson D., Tschanz J.T., Norton M.C., Welsh-Bohmer K.A., Breitner J.C. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch. Neurol. 2004, 61:82-88.
37. Clarke N.A., Francis P.T. Cholinergic and glutamatergic drugs in Alzheimer's disease therapy. Expert Rev. Neurother. 2005, 5:671-682.
38. Racchi M., Mazzucchelli M., Lenzken S.C., Porrello E., Lanni C., Govoni S. Role of acetylcholinesterase inhibitors in the regulation of amyloid beta precursor protein (AbetaPP) metabolism. Chem. Biol. Interact. 2005, 157:335-338.
39. Kaduszkiewicz H., Zimmermann T., Beck-Bornholdt H.P., van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. Br. Med. J. 2005, 331:321-327.
40. Greig N.H., Utsuki T., Ingram D.K., Wang Y., Pepeu G., Scali C., Yu Q.S., Mamczarz J., Holloway H.W., Giordano T., Chen D., Furukawa K., Sambamurti K., Brossi A., Lahiri D.K. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:17213-17218.
41. Ellis J.M. Cholinesterase inhibitors in the treatment of dementia. J. Am. Osteopath. Assoc. 2005, 105:145-158.
42. Zimmermann M., Borroni B., Cattabeni F., Padovani A., Di Luca M. Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiol. Dis. 2005, 19:237-242.
43. Wilkinson D.G., Francis P.T., Schwam E., Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 2004, 21:453-478.
44. Lahiri D.K., Rogers J.T., Greig N.H., Sambamurti K. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. Curr. Pharm. Des. 2004, 10:3111-3119.
45. Zhu X., Raina A.K., Perry G., Smith M.A. Alzheimer's disease: the two-hit hypothesis. Lancet Neurol. 2004, 3:219-226.
46. Herrup K., Neve R., Ackerman S.L., Copani A. Divide and die: cell cycle events as triggers of nerve cell death. J. Neurosci. 2004, 24:9232-9239.
47. Neve R.L., McPhie D.L. The cell cycle as a therapeutic target for Alzheimer's disease. Pharmacol. Ther. 2006, 111:99-113.
48. Tang M.X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B., Andrews H., Mayeux R. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996, 348:429-432.
49. Marlatt M.W., Webber K.M., Moreira P.I., Lee H.G., Casadesus G., Honda K., Zhu X., Perry G., Smith M.A. Therapeutic opportunities in Alzheimer disease: one for all or all for one?. Curr. Med. Chem. 2005, 12:1137-1147.
50. Casadesus G., Zhu X., Atwood C.S., Webber K.M., Perry G., Bowen R.L., Smith M.A. Beyond estrogen: targeting gonadotropin hormones in the treatment of Alzheimer's disease. Curr. Drug Targets CNS Neurol. Disord. 2004, 3:281-285.
51. Devi L., Prabhu B.M., Galati D.F., Avadhani N.G., Anandatheerthavarada H.K. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J. Neurosci. 2006, 26:9057-9068.
52. Parker W.D., Filley C.M., Parks J.K. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 1990, 40:1302-1303.
53. Maurer I., Zierz S., Möller H.J. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol. Aging 2000, 21:455-462.
54. Smith M.A., Perry G., Richey P.L., Sayre L.M., Anderson V.E., Beal M.F., Kowall N. Oxidative damage in Alzheimer's. Nature 1996, 382:120-121.
55. Wang J., Xiong S., Xie C., Markesbery W.R., Lovell M.A. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J. Neurochem. 2005, 93:953-962.
56. Butterfield D.A., Sultana R. Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J. Alzheimers Dis. 2007, 12:61-72.
57. Reddy P.H., McWeeney S., Park B.S., Manczak M., Gutala R.V., Partovi D., Jung Y., Yau V., Searles R., Mori M., Quinn J. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum. Mol. Genet. 2004, 13:1225-1240.
58. Manczak M., Park B.S., Jung Y., Reddy P.H. Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med. 2004, 5:147-162.
59. Manczak M., Anekonda T.S., Henson E., Park B.S., Quinn J., Reddy P.H. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 2006, 15:1437-1449.
60. Manczak M., Mao P., Calkins M.J., Cornea A., Reddy A.P., Murphy M.P., Szeto H.H., Park B., Reddy P.H. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J. Alzheimers Dis. 2010, 20(Suppl. 2):S609-S631.
61. Manczak M., Calkins M.J., Reddy P.H. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum. Mol. Genet. 2011, 20:2495-2509.
62. Manczak M., Reddy P.H. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. Hum. Mol. Genet. 2012, 21:5131-5146.
63. Yao J., Irwin R.W., Zhao L., Nilsen J., Hamilton R.T., Brinton R.D. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14670-14675.
64. Caspersen C., Wang N., Yao J., Sosunov A., Chen X., Lustbader J.W., Xu H.W., Stern D., McKhann G., Yan S.S. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 2005, 19:2040-2041.
65. Devi L., Ohno M. Mitochondrial dysfunction and accumulation of the β-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice. Neurobiol. Dis. 2012, 45:417-424.
66. Hansson Petersen C.A., Alikhani N., Behbahani H., Wiehager B., Pavlov P.F., Alafuzoff I., Leinonen V., Ito A., Winblad B., Glaser E., Ankarcrona M. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13145-13150.
67. Crouch P.J., Blake R., Duce J.A., Ciccotosto G.D., Li Q.X., Barnham K.J., Curtain C.C., Cherny R.A., Cappai R., Dyrks T., Masters C.L., Trounce I.A. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J. Neurosci. 2005, 25:672-679.
68. Reddy P.H. Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease. Brain Res. 2011, 1415:136-148.
69. Duboff B., Feany M., Götz J. Why size matters - balancing mitochondrial dynamics in Alzheimer's disease. Trends Neurosci. Apr 11 2013, (pii: S0166-2236(13)00040-4, [Epub ahead of print]). 10.1016/j.tins.2013.03.002.
70. Hodge T., Colombini M. Regulation of metabolite flux through voltage-gating of VDAC channels. J. Membr. Biol. 1997, 157:271-279.
71. Rostovtseva T., Colombini M. VDAC channels mediate and gate the flow of ATP: implications for the regulation of mitochondrial function. Biophys. J. 1997, 72:1954-1962.
72. Colombini M. VDAC structure, selectivity, and dynamics. Biochim. Biophys. Acta 2012, 1818:1457-1465.
73. Craigen W.J., Graham B.H. Genetic strategies for dissecting mammalian and Drosophila voltage-dependent anion channel functions. J. Bioenerg. Biomembr. 2008, 40:207-212.
74. Yamamoto T., Yamada A., Watanabe M., Yoshimura Y., Yamazaki N., Yoshimura Y., Yamauchi T., Kataoka M., Nagata T., Terada H., Shinohara Y. VDAC1, having a shorter N-terminus than VDAC2 but showing the same migration in an SDS-polyacrylamide gel, is the predominant form expressed in mitochondria of various tissues. J. Proteome Res. 2006, 5:3336-3344.
75. Raghavan A., Sheiko T., Graham B.H., Craigen W.J. Voltage-dependant anion channels: novel insights into isoform function through genetic models. Biochim. Biophys. Acta 2012, 1818:1477-1485.
76. Shimizu S., Narita M., Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1993, 399:483-487.
77. Rostovtseva T.K., Bezrukov S.M. VDAC inhibition by tubulin and its physiological implications. Biochim. Biophys. Acta 2012, 1818:1526-1535.
78. Kerner J., Lee K., Tandler B., Hoppel C.L. VDAC proteomics: post-translation modifications. Biochim. Biophys. Acta 2012, 1818:1520-1525.
79. Lemasters J.J., Holmuhamedov E.L., Czerny C., Zhong Z., Maldonado E.N. Regulation of mitochondrial function by voltage dependent anion channels in ethanol metabolism and the Warburg effect. Biochim. Biophys. Acta 2012, 1818:1536-1544.
80. De Pinto V., Tomasello F.F., Messina A., Guarino F., Benz R., La Mendola D., Magrì A., Milardi D., Pappalardo G. Determination of the conformation of the human VDAC1 N-terminal peptide, a protein moiety essential for the functional properties of the pore. Chembiochem 2007, 8:744-756.
81. Geula S., Ben-Hail D., Shoshan-Barmatz V. Structure-based analysis of VDAC1: N-terminus location, translocation, channel gating and association with anti-apoptotic proteins. Biochem. J. 2012, 444:475-485.
82. Thinnes F.P. Apoptogenic interactions of plasmalemmal type-1 VDAC and Aβ peptides via GxxxG motifs induce Alzheimer's disease - a basic model of apoptosis?. Wien. Med. Wochenschr. 2011, 161:274-276.
83. Jope R.S., Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 2004, 29:95-102.
84. Azoulay-Zohar H., Israelson A., Abu-Hamad S., Shoshan-Barmatz V. In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem. J. 2004, 377:347-355.
85. Hoeflich K.P., Luo J., Rubie E.A., Tsao M.S., Jin O., Woodgett J.R. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000, 406:86-90.
86. Hernandez F., Lucas J.J., Avila J. GSK3 and tau: two convergence points in Alzheimer's disease. J. Alzheimers Dis. 2013, 33(Suppl. 1):S141-S144.
87. Al Sweidi S., Sánchez M.G., Bourque M., Morissette M., Dluzen D., Di Paolo T. Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease. J. Neuroendocrinol. 2012, 24:48-61.
88. Mishra R. Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol. Cancer 2010, 9:144.
89. Fung T.K., Gandillet A., So C.W. Selective treatment of mixed-lineage leukemia leukemic stem cells through targeting glycogen synthase kinase 3 and the canonical Wnt/β-catenin pathway. Curr. Opin. Hematol. 2012, 19:280-286.
90. Mills C.N., Nowsheen S., Bonner J.A., Yang E.S. Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors. Front. Mol. Neurosci. 2011, 4:47.
91. Gao C., Hölscher C., Liu Y., Li L. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev. Neurosci. 2011, 23:1-11.
92. Wang H., Brown J., Martin M. Glycogen synthase kinase 3: a point of convergence for the host inflammatory response. Cytokine 2011, 53:130-140.
93. Bersani F.S., Iannitelli A., Pacitti F., Bersani G. Sleep and biorythm disturbances in schizophrenia, mood and anxiety disorders: a review. Riv. Psichiatr. 2012, 47:365-375.
94. Rasola A., Sciacovelli M., Pantic B., Bernardi P. Signal transduction to the permeability transition pore. FEBS Lett. 2010, 584:1989-1996.
95. Sun T., Rodriguez M., Kim L. Glycogen synthase kinase 3 in the world of cell migration. Dev. Growth Differ. 2009, 51:735-742.
96. Wu D., Pan W. GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem. Sci. 2010, 35:161-168.
97. Kim Y.T., Hur E.M., Snider W.D., Zhou F.Q. Role of GSK3 signaling in neuronal morphogenesis. Front. Mol. Neurosci. 2011, 4:48.
98. Kim Y.M., Seo Y.H., Park C.B., Yoon S.H., Yoon G. Roles of GSK3 in metabolic shift toward abnormal anabolism in cell senescence. Ann. N. Y. Acad. Sci. 2010, 1201:65-71.
99. Pap M., Cooper G.M. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J. Biol. Chem. 1998, 273:19929-19932.
100. Maggirwar S.B., Tong N., Ramirez S., Gelbard H.A., Dewhurst S. HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. J. Neurochem. 1999, 73:578-586.
101. Hetman M., Cavanaugh J.E., Kimelman D., Xia Z. Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J. Neurosci. 2000, 20:2567-2574.
102. Bijur G.N., De Sarno P., Jope R.S. Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J. Biol. Chem. 2000, 275:7583-7590.
103. Bijur G.N., Jope R.S. Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J. Biol. Chem. 2001, 276:37436-37442.
104. Avrahami L., Farfara D., Shaham-Kol M., Vassar R., Frenkel D., Eldar-Finkelman H. Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. J. Biol. Chem. 2013, 288:1295-1306.
105. Ly P.T., Wu Y., Zou H., Wang R., Zhou W., Kinoshita A., Zhang M., Yang Y., Cai F., Woodgett J., Song W. Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J. Clin. Invest. 2013, 123:224-235.
106. Leroy A., Landrieu I., Huvent I., Legrand D., Codeville B., Wieruszeski J.M., Lippens G. Spectroscopic studies of GSK3{beta} phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E. J. Biol. Chem. 2010, 285:33435-33444.
107. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
108. Brazil D.P., Hemmings B.A. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem. Sci. 2001, 26:657-664.
109. Chong Z.Z., Li F., Maiese K. Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog. Neurobiol. 2005, 75:207-246.
110. Martín D., Salinas M., López-Valdaliso R., Serrano E., Recuero M., Cuadrado A. Effect of the Alzheimer amyloid fragment Abeta(25-35) on Akt/PKB kinase and survival of PC12 cells. J. Neurochem. 2001, 78:1000-1008.
111. Henry M.K., Lynch J.T., Eapen A.K., Quelle F.W. DNA damage-induced cell-cycle arrest of hematopoietic cells is overridden by activation of the PI-3 kinase/Akt signaling pathway. Blood 2001, 98:834-841.
112. Cedazo-Mínguez A., Popescu B.O., Blanco-Millán J.M., Akterin S., Pei J.J., Winblad B., Cowburn R.F. Apolipoprotein E and beta-amyloid (1-42) regulation of glycogen synthase kinase-3beta. J. Neurochem. 2003, 87:1152-1164.
113. Ryder J., Su Y., Ni B. Akt/GSK3beta serine/threonine kinases: evidence for a signalling pathway mediated by familial Alzheimer's disease mutations. Cell. Signal. 2004, 16:187-200.
114. Tokutake T., Kasuga K., Yajima R., Sekine Y., Tezuka T., Nishizawa M., Ikeuchi T. Hyperphosphorylation of tau induced by naturally secreted amyloid-β at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3β signaling pathway. J. Biol. Chem. 2012, 287:35222-35233.
115. Baki L., Neve R.L., Shao Z., Shioi J., Georgakopoulos A., Robakis N.K. Wild-type but not FAD mutant presenilin-1 prevents neuronal degeneration by promoting phosphatidylinositol 3-kinase neuroprotective signaling. J. Neurosci. 2008, 28:483-490.
116. Jope R.S., Yuskaitis C.J., Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res. 2007, 32:577-595.
117. Pastorino J.G., Hoek J.B., Shulga N. Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res. 2005, 65:10545-10554.
118. Jo J., Whitcomb D.J., Olsen K.M., Kerrigan T.L., Lo S.C., Bru-Mercier G., Dickinson B., Scullion S., Sheng M., Collingridge G., Cho K. Aβ(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β. Nat. Neurosci. 2011, 14:545-547.
119. Jimenez S., Torres M., Vizuete M., Sanchez-Varo R., Sanchez-Mejias E., Trujillo-Estrada L., Carmona-Cuenca I., Caballero C., Ruano D., Gutierrez A., Vitorica J. Age-dependent accumulation of soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mouse model. J. Biol. Chem. 2011, 286:18414-1825.
120. Wilson J.E. Hexokinases. Rev. Physiol. Biochem. Pharmacol. 1995, 126:65-198.
121. Nakashima R.A., Paggi M.G., Scott L.J., Pedersen P.L. Purification and characterization of a bindable form of mitochondrial bound hexokinase from the highly glycolytic AS-30D rat hepatoma cell line. Cancer Res. 1988, 48:913-919.
122. Abu-Hamad S., Zaid H., Israelson A., Nahon E., Shoshan-Barmatz V. Hexokinase-I protection against apoptotic cell death is mediated via interaction with the voltage-dependent anion channel-1: mapping the site of binding. J. Biol. Chem. 2008, 283:13482-13490.
123. Majewski N., Nogueira V., Bhaskar P., Coy P.E., Skeen J.E., Gottlob K., Chandel N.S., Thompson C.B., Robey R.B., Hay N. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol. Cell 2004, 16:819-830.
124. Pastorino J.G., Shulga N., Hoek J.B. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J. Biol. Chem. 2002, 277:7610-7618.
125. Zaid H., Abu-Hamad S., Israelson A., Nathan I., Shoshan-Barmatz V. The voltage-dependent anion channel-1 modulates apoptotic cell death. Cell Death Differ. 2005, 12:751-760.
126. Yoo B.C., Fountoulakis M., Cairns N., Lubec G. Changes of voltage-dependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down syndrome. Electrophoresis 2001, 22:172-179.
127. Cuadrado-Tejedor M., Vilariño M., Cabodevilla F., Del Río J., Frechilla D., Pérez-Mediavilla A. Enhanced expression of the voltage-dependent anion channel 1 (VDAC1) in Alzheimer's disease transgenic mice: an insight into the pathogenic effects of amyloid-β. J. Alzheimers Dis. 2011, 23:195-206.
128. Hunt A., Schonknecht P., Henze M., Seidl U., Haberkorn U., Schroder J. Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease. Psychiatry Res. Neuroimaging 2007, 155:147-154.
129. Liu F., Shi J., Tanimukai H., Gu J., Gu J., Grundke-Iqbal I., Iqbal K., Gong C.X. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain 2009, 132:1820-1832.
130. Mosconi L., Brys M., Switalski R., Mistur R., Glodzik L., Pirraglia E., Tsui W., De Santi S., de Leon M.J. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19067-19072.
131. Wang D.M., Li S.Q., Zhu X.Y., Wang Y., Wu W.L., Zhang X.P. Protective effects of hesperidin against amyloid-β (Aβ) induced neurotoxicity through the Voltage Dependent Anion Channel 1 (VDAC1)-mediated mitochondrial apoptotic pathway in PC12 cells. Neurochem. Res. 2013, 38:1034-1044.